C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 20.8 CNY -6.47% Market Closed
Market Cap: 21.4B CNY
Have any thoughts about
China Resources Double-Crane Pharmaceutical Co Ltd?
Write Note

Gross Margin
China Resources Double-Crane Pharmaceutical Co Ltd

56.3%
Current
55%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.3%
=
Gross Profit
6.3B
/
Revenue
11.2B

Gross Margin Across Competitors

Country CN
Market Cap 21.4B CNY
Gross Margin
56%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

China Resources Double-Crane Pharmaceutical Co Ltd
Glance View

Market Cap
21.4B CNY
Industry
Pharmaceuticals

China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 11,029 full-time employees. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.

Intrinsic Value
34.08 CNY
Undervaluation 39%
Intrinsic Value
Price
C

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.3%
=
Gross Profit
6.3B
/
Revenue
11.2B
What is the Gross Margin of China Resources Double-Crane Pharmaceutical Co Ltd?

Based on China Resources Double-Crane Pharmaceutical Co Ltd's most recent financial statements, the company has Gross Margin of 56.3%.